# CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

> **NCT06262438** · PHASE2 · RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia in Children

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Etoposide
- **DRUG:** Dexrazoxane
- **DRUG:** Mitoxantrone
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Daunorubicin
- **DRUG:** Fludarabine
- **OTHER:** allo-SCT

## Key facts

- **NCT ID:** NCT06262438
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2028-06
- **Final completion:** 2032-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06262438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06262438, "CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06262438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*